| pubmed-article:9720739 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9720739 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:9720739 | lifeskim:mentions | umls-concept:C1504389 | lld:lifeskim |
| pubmed-article:9720739 | lifeskim:mentions | umls-concept:C0009647 | lld:lifeskim |
| pubmed-article:9720739 | lifeskim:mentions | umls-concept:C0035020 | lld:lifeskim |
| pubmed-article:9720739 | lifeskim:mentions | umls-concept:C0278611 | lld:lifeskim |
| pubmed-article:9720739 | lifeskim:mentions | umls-concept:C0021149 | lld:lifeskim |
| pubmed-article:9720739 | lifeskim:mentions | umls-concept:C1515895 | lld:lifeskim |
| pubmed-article:9720739 | lifeskim:mentions | umls-concept:C1517060 | lld:lifeskim |
| pubmed-article:9720739 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:9720739 | pubmed:dateCreated | 1998-11-16 | lld:pubmed |
| pubmed-article:9720739 | pubmed:abstractText | While allogeneic stem cell transplantation (SCT) is curative for a significant number of patients with AML, relapse of disease within the bone marrow and/or extramedullary (EM) sites following high-dose therapy continues to limit the success of this treatment. Between October 1985 and December 1996, 81 adults underwent allogeneic SCT for de novo AML at our centre. Forty-two patients remain alive and free of leukaemia with a median follow-up of 50 months. The 5-year actuarial event-free survivals (EFS) for all patients and for those undergoing SCT in CR1 or with advanced disease were 46% (95% confidence interval (CI) 34-58%), 63% (CI 46-76%), and 19% (CI 7-36%), respectively. Twenty-two patients relapsed at a median of 8 (range 1.6-54.5) months with the actuarial risk of relapse for all, CR1 and advanced disease patients being 38%, (CI 27-52%), 23% (CI 13-40%) and 68% (CI 46-88%), respectively. Ten patients relapsed at EM sites; six of these (27% of relapses) had an isolated EM relapse at a median of 31 (range 8.5-54) months. Three of the patients with isolated EM relapse survived > or =24 months following relapse and two patients remain disease-free at 29+ and 33+ months. BuCy conditioning followed by allogeneic SCT in AML results in satisfactory EFS although there is a significant risk of late isolated EM relapse. | lld:pubmed |
| pubmed-article:9720739 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9720739 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9720739 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9720739 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9720739 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9720739 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9720739 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9720739 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:9720739 | pubmed:issn | 0268-3369 | lld:pubmed |
| pubmed-article:9720739 | pubmed:author | pubmed-author:SimpsonD RDR | lld:pubmed |
| pubmed-article:9720739 | pubmed:author | pubmed-author:ShepherdJ DJD | lld:pubmed |
| pubmed-article:9720739 | pubmed:author | pubmed-author:NaimanS CSC | lld:pubmed |
| pubmed-article:9720739 | pubmed:author | pubmed-author:KlingemannH... | lld:pubmed |
| pubmed-article:9720739 | pubmed:author | pubmed-author:SutherlandH... | lld:pubmed |
| pubmed-article:9720739 | pubmed:author | pubmed-author:VickarsL MLM | lld:pubmed |
| pubmed-article:9720739 | pubmed:author | pubmed-author:HoggeD EDE | lld:pubmed |
| pubmed-article:9720739 | pubmed:author | pubmed-author:BarnettM JMJ | lld:pubmed |
| pubmed-article:9720739 | pubmed:author | pubmed-author:NantelS HSH | lld:pubmed |
| pubmed-article:9720739 | pubmed:author | pubmed-author:NevillT JTJ | lld:pubmed |
| pubmed-article:9720739 | pubmed:author | pubmed-author:HorsmanD EDE | lld:pubmed |
| pubmed-article:9720739 | pubmed:author | pubmed-author:ELOYRR | lld:pubmed |
| pubmed-article:9720739 | pubmed:author | pubmed-author:TozeC LCL | lld:pubmed |
| pubmed-article:9720739 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9720739 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:9720739 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9720739 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9720739 | pubmed:pagination | 259-64 | lld:pubmed |
| pubmed-article:9720739 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:9720739 | pubmed:meshHeading | pubmed-meshheading:9720739-... | lld:pubmed |
| pubmed-article:9720739 | pubmed:meshHeading | pubmed-meshheading:9720739-... | lld:pubmed |
| pubmed-article:9720739 | pubmed:meshHeading | pubmed-meshheading:9720739-... | lld:pubmed |
| pubmed-article:9720739 | pubmed:meshHeading | pubmed-meshheading:9720739-... | lld:pubmed |
| pubmed-article:9720739 | pubmed:meshHeading | pubmed-meshheading:9720739-... | lld:pubmed |
| pubmed-article:9720739 | pubmed:meshHeading | pubmed-meshheading:9720739-... | lld:pubmed |
| pubmed-article:9720739 | pubmed:meshHeading | pubmed-meshheading:9720739-... | lld:pubmed |
| pubmed-article:9720739 | pubmed:meshHeading | pubmed-meshheading:9720739-... | lld:pubmed |
| pubmed-article:9720739 | pubmed:meshHeading | pubmed-meshheading:9720739-... | lld:pubmed |
| pubmed-article:9720739 | pubmed:meshHeading | pubmed-meshheading:9720739-... | lld:pubmed |
| pubmed-article:9720739 | pubmed:meshHeading | pubmed-meshheading:9720739-... | lld:pubmed |
| pubmed-article:9720739 | pubmed:meshHeading | pubmed-meshheading:9720739-... | lld:pubmed |
| pubmed-article:9720739 | pubmed:meshHeading | pubmed-meshheading:9720739-... | lld:pubmed |
| pubmed-article:9720739 | pubmed:meshHeading | pubmed-meshheading:9720739-... | lld:pubmed |
| pubmed-article:9720739 | pubmed:meshHeading | pubmed-meshheading:9720739-... | lld:pubmed |
| pubmed-article:9720739 | pubmed:meshHeading | pubmed-meshheading:9720739-... | lld:pubmed |
| pubmed-article:9720739 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9720739 | pubmed:articleTitle | High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation. | lld:pubmed |
| pubmed-article:9720739 | pubmed:affiliation | Division of Hematology, British Columbia Cancer Agency, Vancouver Hospital and Health Sciences Centre, Canada. | lld:pubmed |
| pubmed-article:9720739 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9720739 | lld:pubmed |
